ZA200705515B - Preparation of ketone amides - Google Patents
Preparation of ketone amides Download PDFInfo
- Publication number
- ZA200705515B ZA200705515B ZA200705515A ZA200705515A ZA200705515B ZA 200705515 B ZA200705515 B ZA 200705515B ZA 200705515 A ZA200705515 A ZA 200705515A ZA 200705515 A ZA200705515 A ZA 200705515A ZA 200705515 B ZA200705515 B ZA 200705515B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- reaction
- protic solvent
- compound
- phase
- Prior art date
Links
- -1 ketone amides Chemical class 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000000034 method Methods 0.000 claims description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 17
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 239000012071 phase Substances 0.000 claims description 14
- 239000003586 protic polar solvent Substances 0.000 claims description 14
- 239000012429 reaction media Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 239000012320 chlorinating reagent Substances 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 4
- 239000012074 organic phase Substances 0.000 claims description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 229940117389 dichlorobenzene Drugs 0.000 claims description 3
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- 101100439689 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chs-4 gene Proteins 0.000 claims 1
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 description 3
- 102000004274 CCR5 Receptors Human genes 0.000 description 2
- 108010017088 CCR5 Receptors Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000012431 aqueous reaction media Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- PMFHDJUZVJBPJK-UHFFFAOYSA-N 1-(2,4-dimethylpyridine-3-carbonyl)piperidin-4-one Chemical compound CC1=CC=NC(C)=C1C(=O)N1CCC(=O)CC1 PMFHDJUZVJBPJK-UHFFFAOYSA-N 0.000 description 1
- WFMISPSCYRPERO-UHFFFAOYSA-N 1-(2,4-dimethylpyrimidine-5-carbonyl)piperidin-4-one Chemical compound CC1=NC(C)=NC=C1C(=O)N1CCC(=O)CC1 WFMISPSCYRPERO-UHFFFAOYSA-N 0.000 description 1
- XOXCPJHUHAPCBD-UHFFFAOYSA-N 2,6-dimethyl-2H-pyrimidine-1-carboxylic acid Chemical compound CC1N=CC=C(C)N1C(O)=O XOXCPJHUHAPCBD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- SXWRTZOXMUOJER-UHFFFAOYSA-N hydron;piperidin-4-one;chloride;hydrate Chemical compound O.Cl.O=C1CCNCC1 SXWRTZOXMUOJER-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- VRJHQPZVIGNGMX-UHFFFAOYSA-N piperidine-4-one Natural products O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64189905P | 2005-01-06 | 2005-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200705515B true ZA200705515B (en) | 2008-05-28 |
Family
ID=36283752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200705515A ZA200705515B (en) | 2005-01-06 | 2007-07-05 | Preparation of ketone amides |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7759487B2 (fr) |
| EP (1) | EP1838695A2 (fr) |
| JP (2) | JP4728350B2 (fr) |
| CN (1) | CN101133046B (fr) |
| AR (1) | AR052864A1 (fr) |
| CA (1) | CA2594106A1 (fr) |
| MX (1) | MX2007008214A (fr) |
| SG (1) | SG158857A1 (fr) |
| WO (1) | WO2006074264A2 (fr) |
| ZA (1) | ZA200705515B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101139343A (zh) * | 2002-03-29 | 2008-03-12 | 先灵公司 | 作为ccr5拮抗药的哌啶和哌嗪化合物的合成 |
| AR052864A1 (es) * | 2005-01-06 | 2007-04-11 | Schering Corp | Preparacion de cetoamidas |
| WO2009128947A1 (fr) | 2008-04-17 | 2009-10-22 | Concert Pharmaceuticals, Inc. | Dérivés de pipérazine |
| WO2020038755A1 (fr) * | 2018-08-21 | 2020-02-27 | Huntsman International Llc | Catalyseur pour la production de mousse pir/pur |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466687A (en) * | 1992-10-22 | 1995-11-14 | Dr. Karl Thomae Gmbh | Arylidene-1-azacycloalkanes and arylalkyl-1-azacyclo-alkanes, their salts, medicaments containing these compounds and their use, and processes for their preparation |
| US5376666A (en) * | 1992-11-30 | 1994-12-27 | The Du Pont Merck Pharmaceutical Company | Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl |
| DE4426671A1 (de) * | 1994-07-28 | 1996-02-01 | Hoechst Ag | Verfahren zur Kreuzkupplung von aromatischen Borverbindungen mit aromatischen Halogenverbindungen oder Perfluoralkylsulfonaten |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| US6689765B2 (en) | 1999-05-04 | 2004-02-10 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| US6410750B1 (en) * | 1999-06-18 | 2002-06-25 | Pfizer Inc. | Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid |
| DK1438316T3 (da) * | 2001-10-19 | 2006-10-16 | Ortho Mcneil Pharm Inc | Phosphonsyreforbindelser som inhibitorer af serinproteaser |
| CN101139343A (zh) | 2002-03-29 | 2008-03-12 | 先灵公司 | 作为ccr5拮抗药的哌啶和哌嗪化合物的合成 |
| AR052864A1 (es) * | 2005-01-06 | 2007-04-11 | Schering Corp | Preparacion de cetoamidas |
-
2006
- 2006-01-05 AR ARP060100037A patent/AR052864A1/es unknown
- 2006-01-05 WO PCT/US2006/000251 patent/WO2006074264A2/fr active Application Filing
- 2006-01-05 EP EP06717452A patent/EP1838695A2/fr not_active Withdrawn
- 2006-01-05 US US11/326,156 patent/US7759487B2/en not_active Expired - Fee Related
- 2006-01-05 JP JP2007550444A patent/JP4728350B2/ja not_active Expired - Fee Related
- 2006-01-05 MX MX2007008214A patent/MX2007008214A/es active IP Right Grant
- 2006-01-05 SG SG201000064-4A patent/SG158857A1/en unknown
- 2006-01-05 CA CA002594106A patent/CA2594106A1/fr not_active Abandoned
- 2006-01-05 CN CN2006800065103A patent/CN101133046B/zh not_active Expired - Fee Related
-
2007
- 2007-07-05 ZA ZA200705515A patent/ZA200705515B/en unknown
-
2009
- 2009-09-22 US US12/564,504 patent/US20100029939A1/en not_active Abandoned
-
2011
- 2011-02-16 JP JP2011031434A patent/JP2011102328A/ja not_active Withdrawn
- 2011-11-23 US US13/303,272 patent/US20120065397A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7759487B2 (en) | 2010-07-20 |
| MX2007008214A (es) | 2007-08-17 |
| CA2594106A1 (fr) | 2006-07-13 |
| WO2006074264A2 (fr) | 2006-07-13 |
| EP1838695A2 (fr) | 2007-10-03 |
| CN101133046B (zh) | 2011-08-03 |
| JP4728350B2 (ja) | 2011-07-20 |
| US20120065397A1 (en) | 2012-03-15 |
| JP2008526860A (ja) | 2008-07-24 |
| US20060247437A1 (en) | 2006-11-02 |
| CN101133046A (zh) | 2008-02-27 |
| WO2006074264A3 (fr) | 2006-11-02 |
| JP2011102328A (ja) | 2011-05-26 |
| US20100029939A1 (en) | 2010-02-04 |
| AR052864A1 (es) | 2007-04-11 |
| SG158857A1 (en) | 2010-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6511346B2 (ja) | ハロゲン化環式化合物の合成方法 | |
| US6433179B1 (en) | Process for producing paroxetine | |
| HUE029528T2 (en) | Process for the preparation of 6- (7 - ((1-aminocyclopropyl) methoxy) -6-methoxyquinolin-4-yloxy) -N-methyl-1-naphthamide and its synthetic intermediates | |
| ZA200705515B (en) | Preparation of ketone amides | |
| WO2018214686A1 (fr) | Procédé de préparation d'un composé d'isoxazinone et utilisation associée | |
| US7220863B2 (en) | Process for preparing 2-aminopyridine derivatives | |
| US8476470B2 (en) | Process for production of bicyclo[2.2.2]octylamine derivative | |
| AU2013215796A1 (en) | Method for preparing compound by novel Michael addition reaction using water or various acids as additive | |
| KR20190013554A (ko) | 아미노피리미딘 유도체의 합성에 유용한 신규의 중간체, 이의 제조방법 및 이를 이용한 아미노피리미딘 유도체의 제조방법 | |
| US6462195B1 (en) | Methods for highly selectively o-alkylating amide compounds with the use of copper salts | |
| JP3252484B2 (ja) | ４，５−ジヒドロ［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体の製造方法 | |
| JP4663105B2 (ja) | ２−スルホニル−４−オキシピリジン誘導体の製造方法 | |
| KR100382715B1 (ko) | 4-히드록시티오쿠마린 및 그의 질소 유사체의 제조방법 | |
| SK72196A3 (en) | Method for producing 1-{£2-(cyclopropylcarbonyl)- phenyl| sulfamoyl}-3-(4,6-dialkoxy-2-pyrimidinyl) of urea and intermediate products of this method | |
| EP1674451A1 (fr) | Procede de production de n, n'-dialcoxy-n, n'-dialkyl oxamide | |
| KR20180093307A (ko) | 4, 5-디아미노 치환 피리미딘 유도체의 제조방법 및 이를 제조하기 위한 신규한 화합물 | |
| JPWO2004108680A1 (ja) | 光学活性なキノロンカルボン酸誘導体の製造中間体およびその製造法 | |
| CZ296784B6 (cs) | Zpusob výroby esteru kyseliny aryliminomethylkarbamové | |
| WO2000063184A1 (fr) | Procede de production de 2-(alkylthio)-4-chloropyrimidines | |
| JPH09316056A (ja) | 環状ニトログアニジン誘導体の製造法 | |
| JPH06774B2 (ja) | ピロ−ル誘導体の製造方法 | |
| JPH08333344A (ja) | ナフトエ酸エステル誘導体及びその製造方法 | |
| JP2001278864A (ja) | ４−メトキシキノリン類の製造方法 | |
| JPWO2003095446A1 (ja) | １−（４−ピリジル）−４−ピペリドンの製造方法 | |
| SK169397A3 (en) | Aminophenyl ketone derivatives and preparation method thereof |